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Cancer stem cells (CSCs) have been the 
subject of intensive discussion and investi-
gation for decades. Not surprisingly, what 
is meant by the term CSC has evolved over 
that period. Historically, it first invoked the 
concept that malignant cell populations are 
organized as unidirectional cellular hierar-
chies in which CSCs constitute biologically 
unique subsets of cells, which are distin-
guished from the bulk of the cells that they 
produce by their exclusive ability to perpetu-
ate the growth of a malignant cell population 
indefinitely1–4. This concept is of considerable 
clinical importance because it emphasizes 
the crucial need to target CSCs to achieve 
cures. It also offers a possible explanation as 
to why many treatments seem to be effective 
initially but the patient later relapses. The 
implication is that CSCs are often innately 
less sensitive to treatment than are the bulk 
of the tumour cells that they generate. As a 
result, the tumour may initially appear to 
be eliminated, but it later reappears because 
the rarer and grossly invisible populations of 
CSCs have survived. In addition to the inher-
ent insensitivity of some CSCs to currently 
used anticancer drugs, continuing genomic 
and epigenomic changes are believed to con-
fer new treatment-resistant properties that 
are then passed on to daughter generations 
of CSCs and their progeny5–9. Interactions of 
CSCs with their microenvironment (CSC 
niches) may also contribute to an ability to 
resist treatment9–13.
These clinically important issues have 
stimulated intense interest in experimental 
approaches for investigating CSCs. They 
point to a particular need for better methods 
to identify and distinguish individual human 
tumours in which a unidirectional hierarchy 
is evident at diagnosis and those in which 
such a hierarchy does not seem to be in 
place. This lack of hierarchy arises when all 
or most of the tumour cells have CSC prop-
erties, independently of their evolving geno-
type or phenotype, or when the mechanisms 
that regulate the CSC state have become 
unstable (reversible).
More recently, the term CSC has become 
associated with the operational detection of 
cells with CSC properties. In this case, the 
term refers to cells shown (retrospectively) 
to have been capable of generating and 
propagating a malignant cell population, 
usually identified and characterized in an 
experimental setting. Given the potential 
importance of information that could be 
derived from experimental systems and 
assays that are able to detect CSCs in cancer 
patients, there is now considerable interest 
in both the value of available methods and 
the properties and responses of the cells that 
they identify.
Current approaches use transplanted 
immunodeficient mice to characterize the 
ability of CSCs to regenerate malignant 
populations that resemble the parental cancer 
in vivo. This powerful strategy has been suc-
cessfully applied to the detection of CSCs in 
many types of human cancers1–4,9,12. Sphere 
formation in non-adherent cultures has 
been used as a surrogate in vitro method for 
detecting CSCs from some primary human 
tumours14–18. This in vitro approach has the 
advantage of being cheaper and faster, but 
also has the shortcoming of being reliant on 
a less physiological end point. Nevertheless, 
advances made using both approaches suggest 
their usefulness for developing more direct 
CSC detection methods that might be clini-
cally meaningful. Examples include pheno-
typic and transcriptional marker profiles, 
assuming that these can be found to show 
sufficient stability, generality and specificity. 
However, given the extent of the genomic and 
phenotypic heterogeneity of malignant popu-
lations now known to characterize tumours 
of the same histological appearance and grade 
(including the CSCs that they contain), this 
goal is posing a considerable challenge.
The Year 2011 Working Conference on 
CSCs was organized to review and discuss 
these issues. The key points of discussion 
and the conclusions that were reached are 
summarized below.
CSC definitions and terminology
Stem cells in normal tissues are generally 
defined as undifferentiated cells that have 
the capacity to produce the specialized end 
cells of that tissue, as well as undifferentiated 
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descendant stem cells with tissue-maintaining 
potential. This paradigm was first estab-
lished in the haematopoietic system in mice 
and humans and has since been extended 
to many other tissues in both species3. 
Interestingly, it has also become apparent 
that even stringently defined normal tis-
sue stem cells with extensive self-renewal 
properties can be intrinsically heterogeneous 
with regard to their differentiation and self-
renewal control in different sites or stages of 
development19–21. Thus, heterogeneity among 
CSCs in a single tumour type, or even within 
a single tumour, cannot be assumed to be 
indicative of an abnormal (tumour-specific) 
process or to be a consequence of a DNA 
mutation. Indeed, altered function of epige-
netic regulators is rapidly emerging as a very 
prevalent feature of malignant populations6.
The idea that normal tissues are organ-
ized as fairly fixed developmental hierarchies 
derives from the assumption that differentia-
tion involves the sequential activation of a 
series of molecular processes that coordinate 
discrete changes in a unidirectional and 
highly organized manner22 (FIG. 1). This 
model is based on the observed consistency 
of the process under homeostatic conditions. 
Because the changes may span multiple cell 
divisions, the process may allow separable 
subtypes of transit-amplifying cells to be 
distinguished23–25. Accordingly, normal 
tissue cells at sequential early stages of diff-
erentiation can now often be discriminated 
with great precision by immuno logical or 
molecular profiling — much greater than is 
achievable by morphology.
Phenotypic descriptions of normal tissue 
hierarchies have thus been powerful tools 
that enable direct analyses of changes that 
accompany, or that are even part of, the nor-
mal differentiation process. However, as yet, 
in no instance has a profile been identified 
that can reliably replace functional assays for 
normal stem cells. It should also be noted 
that many of the phenotypic markers found 
to be empirically useful for isolating particu-
lar subsets of cells in unperturbed normal 
tissue have proved to be functionally dispen-
sable or differently regulated when they are 
activated in vivo or in vitro3,4. In addition, 
there is increasing evidence that normal tis-
sue stem cells that are identified by their  
tissue-regenerative activity in different assays 
may fail to include cells with similar latent 
potentialities that are only revealed under 
different conditions. Examples of this situa-
tion have recently been documented for sev-
eral epithelial tissues in the mouse, including 
the skin, mammary gland and intestine21. 
Memory T and B lymphocytes also represent 
anomalous differentiated cells that seem to 
have a very extensive innate self-renewal 
ability. Thus, exactly when a normal tissue 
cell loses the molecular machinery required 
to allow it to function like a stem cell is no 
longer as clearcut as the original concept of 
unidirectional differentiation suggested.
Tumours are known to arise from single 
cells in specific tissues through a series of 
genetic and/or epigenetic events that begin 
by interfering with mechanisms that  
normally control a stable physiological 
cell output in that tissue or that initiate 
a genomically unstable state5–8. This has 
given weight to the idea that cancer typi-
cally evolves from abnormal clones that, at 
least initially, preserve many features of the 
hierarchical structure of the normal tissue 
in which the malignancy has arisen (FIG. 1). 
An important feature of normal tissue hier-
archies is the tight linkage between observed 
differentiation-associated transcriptional, 
phenotypic and morphological changes and 
an accompanying loss of proliferative ability. 
Observations of early stage (pre-malignant) 
conditions suggest that these usually main-
tain many of the hallmarks of normal differ-
entiation. At this stage, clonal amplification 
seems to reflect an increased self-renewal 
and proliferative activity and/or survival of 
primitive cells with continued differentiation 
and the production of large numbers of cells 
that are incapable of further division. The 
CSC concept implies that the production of 
cells that are incapable of further division 
is often retained even when more readily 
detected indicators of differentiation are 
blocked or lost.
Figure 1 | Models of cancer stem cell evolution: perturbation of the normal differentiation 
hierarchy. A schematic comparison is shown of the highly coordinated and quantitativ ly regulat d 
hierarchy of normal tissue populations in which cell turnover is a feature of tissue maintenance (top of 
figure), with stem cells giving rise to transit-amplifying cells that are differentiating (shown by dashed 
circles), to finally produce the mature cells of the tissue that are incapable of further division. During 
the evolution of malignant populations, the effects of alterations imposed by the sequential acquisition 
of mutations and/or epigenetic changes (indicated by the colour change) will first deregulate cell pro-
duction and then lead to clonal expansion (middle of figure). Ultimately, a full-blown malignant clone 
may be produced. Such cells have typically acquired a complex profile of aberrations (indicated by 
multiple colours) and a loss of many features of normal differentiation characteristic of the transit-
amplifying compartment (bottom of figure). In this particular schema, neoplastic stem cells are shown 
as developing from normal stem cells, although multiple alternative scenarios in which neoplastic stem 
cells arise from pre-malignant cells with ‘later’ phenotypes or biology can be envisaged (dashed arrow).
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The term neoplasia is widely used to cover 
all scenarios in which a clone of cells appears 
to display perturbed growth properties. 
This contrasts with other abnormal condi-
tions that represent reactive (polyclonal) 
responses to an external stimulus (although 
the development of a neoplastic clone may 
emerge from a prior polyclonal response). 
Neoplasias thus include pre-malignant and 
overtly malignant conditions. Pre-malignant 
neoplastic conditions are usually character-
ized by a greater (but usually unpredictable) 
clonal stability than malignant diseases. Pre-
malignant conditions also have no immedi-
ate cancer-generating potential. As a result, 
their subsequent clinical course is also unpre-
dictable. Nevertheless, they may, over time, 
progress to a full-blown malignant state with 
invasive properties. Examples include mono-
clonal gammopathy of unknown significance 
(MGUS), early stages of myeloproliferative 
neoplasms (MPNs), (pre-malignant) colonic 
adenoma, Barrett’s oesophagus, pre-invasive 
dysplasia and in situ carcinoma. Conversely, 
most spontaneously arising human malig-
nancies5–8 (although not all26) are thought 
to represent subclonal derivatives that arise 
slowly and that evolve progressively from 
pre-malignant clones (FIG. 2).
Accordingly, we propose that neoplastic 
stem cells should be classified according to 
the same principles that have historically 
been established for neoplastic populations 
(TABLE 1). Neoplastic stem cells would thus 
include both pre-malignant neoplastic stem 
cells and malignant neoplastic stem cells, 
and only the malignant neoplastic stem cells 
would meet the definition of CSCs. Both 
types of neoplastic stem cells would thus 
refer exclusively to cells with the potential to 
propagate (maintain) a neoplastic popula-
tion for a prolonged or unlimited period, 
and the term CSCs would be retained exclu-
sively for cells that produce an overt invasive 
tumour or leukaemia.
These definitions make no inference 
about the normal cell in which the process 
of transformation was initiated, nor about 
the cell type in which a malignant state 
might first have been achieved. Indeed, they 
accommodate the possibility that disease 
progression can occur independently in  
different members of a pre-malignant clone7 
(FIG. 2). They also imply that pre-malignant 
neoplastic stem cells have self-renewal 
capacity and produce daughter cells with 
limited proliferative potential.
An important feature of neoplastic stem 
cells is their extensive genomic (subclonal) 
heterogeneity. This is evident both in com-
parisons of different patients’ tumours that 
are classified as similar morphologically, and 
in a single tumour5–8,27. Such heterogeneity 
reflects the accrual and transmission of vary-
ing combinations of molecular lesions and 
oncogenic pathways that operate in continu-
ously diversifying subclones (FIG. 2). These 
subclones have varying malignant potentials 
because of the molecular heterogeneity of 
their propagating stem cells and the differ-
ent microenvironmental interactions that 
they may experience. A corollary to this view 
is that any persistent cancer subclone will 
contain a compartment of neoplastic stem 
cells with a unique genomic and epigenomic 
profile, recognizing that each subclone that 
develops may be a source of future new 
subclones with somewhat altered properties. 
As soon as one of the cells within such a sub-
clone undergoes sufficient further change to 
acquire fully malignant potential, it becomes 
a CSC that, itself, may generate further 
altered CSCs (FIG. 2).
When the term CSC is used in an opera-
tional, rather than a conceptual, context, 
additional issues become important, as 
well as the nomenclature used. The terms 
cancer initiating, cancer propagating, can-
cer maintaining and repopulating have 
often been used to describe experimentally 
detected CSCs because these terms seem 
to offer greater specificity. However, they 
can also be a source of confusion. The term 
cancer initiating does not clearly distinguish 
between the original cells from which the 
malignancy first arose and the cells in a 
given suspension that are capable of pro-
ducing malignant daughter cells in a given 
assay. However, the term cancer initiating 
Figure 2 | Proposed model of cancer stem cell evolution. A schematic representation is shown 
of the continuously branching network of subclones envisaged to accompany the expansion of an 
initially mutated or epigenetically altered cell, thereby gaining a proliferative advantage over its nor-
mal counterparts that is sufficient to create a persistent neoplastic clone. This initial clone may pro-
duce distinct subclones that are controlled by the natural immune system and/or the environment of 
the surrounding tissue or organ (dashed rectangles) and hence these do not produce an overt malig-
nancy. In this first phase of cancer evolution (phase I), neoplastic stem cells (indicated by blue outlines) 
are pre-malignant stem cells. However, if one or more subclones acquires a particular profile of hits 
(indicated by colour changes), an overt malignancy develops. At that time (phase II), the neoplastic 
stem cells become cancer-initiating cells and can thus be called cancer stem cells (CSCs) (indicated 
by black outlines). However, the other neoplastic subclones and their stem cells may remain and con-
tinue to generate additional pre-malignant and/or malignant subclones. The term pre-malignant 
(or pre-leukaemic) neoplastic stem cells is thus best confined to cells shown retrospectively (or experi-
mentally) to be forerunners of malignant stem cells, whereas those that may never transform further 
are more accurately referred to simply as neoplastic (pre-malignant).
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does have the advantage of being a variant of 
similar terms that have already been estab-
lished in the stem cell literature; for example, 
as in the terms, long-term culture-initiating 
cell (LTC-IC)28, neurosphere-initiating cell 
(NS-IC)29 or mammosphere-initiating cell 
(M-IC)30. But the term cancer-initiating  
cell should then be confined in its applica-
tion to cells that are shown to initiate the for-
mation of a progressively growing malignant 
population. The terms cancer propagating or 
cancer maintaining may be more accurate, 
at least in the context of xenotransplan tation 
models; and the term long-term cancer 
propagating (or cancer maintaining) may 
help to further qualify the cells detected. 
The term repopulating has the advantage 
of implying an in vivo read out, but fails to 
highlight the cancer aspect of the repopula-
tion and seems misleading, as it is a normal 
tissue of the host that is being repopulated 
with malignant cells. However, all of these 
terms highlight the need to designate the 
follow-up time adopted, or specify the use of 
serial transplantation experiments to meet 
the criterion of long term.
These considerations further highlight 
the importance of clearly specifying the 
protocol details that are associated with 
any term used to refer to an operationally 
identified CSC entity (TABLE 1). The discrimi-
nating power and hence the utility of the 
term CSC lies in the validity of the assump-
tions and inferences that are associated with 
its use. These, in turn, can only be examined 
and appreciated if the experimental details 
used to define a CSC as such are explicit.
When a clonal hierarchy is in question
The idea that malignant cell populations are 
hierarchically organized seems logical given 
the evidence for their stepwise evolution 
from cells in normal tissues. Experimental 
evidence for human CSCs is considered to 
be best established by demonstrating the 
ability of cells that are directly isolated from 
patients to produce malignant daughter 
populations in transplanted immuno-
deficient mice. This approach was pioneered 
with samples of cells from patients with 
various types of leukaemia (acute lymphoid 
leukaemia (ALL)31, acute myeloid leukaemia 
(AML)32 and chronic myeloid leukaemia 
(CML)33). Subsequently, the same approach 
has been successfully applied to solid 
tumours, including human cancers arising 
in the breast34, brain14, colon16,35, ovary36, 
lung17, and head and neck37. One criterion 
used to establish that these CSCs are biologi-
cally different from the bulk of the cells in 
the tumour has been the demonstration that 
they have a distinct phenotype that allows 
their prospective and selective enrichment. 
However, in most cases, the phenotype of 
cells meeting the very stringent functional 
definition of a CSC (tumour-initiating activ-
ity in an immunodeficient mouse at the 
single-cell level) has not proved to be  
singular or even stable.
For example, CD34+CD38+ AML cells, 
as well as CD34+CD38− AML cells, both 
frequently show CSC activity when trans-
planted into non-obese diabetic, severe 
combined immunodeficient (NOD/SCID) 
mice lacking a functional IL2RG chain 
(NSG or NOG) mice, although previ-
ously, this property seemed to be mostly 
restricted to the CD34+CD38− subset when 
less immunodeficient NOD/SCID mice 
were used as recipients38,39. Nevertheless, 
a hierarchy of cells can still be found to 
exist within these leukaemias40. In addi-
tion, perturbations of differentiation that 
affect normal lineage restriction processes 
(for example, as found in biphenotypic 
leukaemias), or the production of abnormal 
phenotypes, are well documented con-
sequences of leukaemogenesis41. Similar 
examples of coexisting or unstable CSC 
phenotypes have also been reported in 
human ALL42 and several types of human 
solid tumours36,43–45. These findings high-
light the fact that malignant cells have 
perturbed gene expression programmes 
that might affect the normal stability or the 
developmental control of the expression of 
certain cell surface markers, particularly 
when the cells are put in vitro. Thus pheno-
type data alone have not proved sufficient 
to infer the existence of a developmental 
hierarchy or the presence of a CSC.
In some malignancies, even functional 
xenotransplantation evidence of a persisting 
hierarchical structure in a malignant popu-
lation is not apparent. Advanced human 
malignant melanoma is one such example46. 
For such malignancies, the utility of experi-
mental assays for CSCs per se, will have 
weaker clinical relevance. Nevertheless, the 
use of xenografts to evaluate their responses 
to novel treatments in vivo remains an 
attractive possibility. Such advanced 
tumours do not negate the validity of the 
CSC concept, as tumorigenesis is known to 
be a multistep process in which more aggres-
sive subclones typically supplant a preceding 
clone in which a hierarchy did exist.
It has recently been suggested that the 
very molecular mechanisms that confer 
CSC properties on cells within malignant 
clones; that is, the CSC state, may also be 
 Table 1 | Terms to define cancer stem cells and required associated information
Type of cells Definition
Conceptual context
Pre-malignant neoplastic 
stem cells
A subclass of neoplastic stem cells that can propagate neoplastic 
clones that may or may not develop into cancer stem cells over 
time, but that have no immediate cancer-initiating potential
Cancer stem cells (malignant 
neoplastic stem cells)
A subclass of neoplastic stem cells that propagate malignant 
clones indefinitely and produce an overt cancer 
Operational context
Neoplasia-initiating cells  
(in vivo)
Cells that regenerate detectable neoplastic* populations in 
xenografted immunodeficient mice that are sustained‡, usually 
measured by LDA 
Tumour or leukaemia- 
initiating cells
A subclass of neoplastic stem cells that regenerate 
detectable, sustained‡ malignant* populations in xenografted 
immunodeficient mice, usually measured by LDA 
Neoplastic long-term  
culture-initiating cells
Cells that can initiate the sustained§ production of neoplastic* 
populations when cultured in supportive conditions (for 
example, with stromal cells); can include pre-malignant and 
malignant neoplastic cells, usually measured by LDA 
Neoplastic sphere-forming 
cells
Cells that can initiate the production of non-adherent 
‘spheres’ of neoplastic progeny in in vitro cultures, can include 
pre-malignant and malignant neoplastic cells, usually measured 
by counting spheres that can generate secondary spheres when 
re-plated (assumes spheres can be shown to be clones)
LDA, limiting dilution analysis. *Defined by obviously abnormal biological features exhibited by cells in the 
primary sample (for example, the formation of a palpable growth or tumour; the production of leukaemic 
blasts; abnormal growth properties; and abnormal karyotype or genotype). ‡Based on experience, 
adapting this approach to normal stem cells, in this context sustained usually means ≥16 weeks, and 
ideally demonstrable activity on serial transplantation into secondary mice. §Based on experience, 
adapting this approach to normal stem cells, in this context sustained usually means ≥6 weeks with 
stromal cells ± stimulatory growth factors.
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unstable47–50. This is an intriguing idea par-
ticularly in light of the growing number of 
major regulators of the epigenome that are 
commonly altered in malignant popula-
tions51. In addition, we now know that only 
a handful of oncogenes can turn almost any 
mammalian cell into an embryonic stem cell 
(ESC)-like cell, which often retains tumori-
genic potential even after participating in 
normal embryogenesis52. However, whether 
reprogramming has an important role in the 
generation and evolution of human tumours 
is unknown and will also be very challenging 
to investigate, as functional assays attribute a 
CSC state exclusively to cells that display a 
sustained tumour-generating ability (in vivo).
CSC assays: strengths and caveats
To date, immunodeficient mice have proved 
the most sensitive recipients for support-
ing the growth of many sources of human 
CSCs and have made it possible to develop 
in vivo assays to detect and quantify these 
cells. However, the ability or failure of a 
cell to produce a detectable malignant 
population in a transplanted mouse might 
not accurately reflect its behaviour in a 
cancer patient. The limitations of currently 
available xenotransplantation models and 
possibilities for overcoming these limita-
tions are shown in TABLE 2. Continued 
genetic modifications of candidate host 
mice will probably enable at least some of 
the species-specific needs to be addressed 
in the future. These include the possibility 
of creating transgenic mice that will express 
species-specific human cytokines, or the 
use of humanized mice (mice transplanted 
with human haematopoietic or local tissue 
components) to create more human-type 
microenvironments  — as has proved useful 
for certain types of normal human cells53–57. 
Orthotopic injections of CSCs into vari-
ous target organs may also prove useful, 
and mimicry of natural tumour immuno-
surveillance mechanisms may be achievable 
using injections of specific immune effector 
cells (TABLE 2).
Attempts have also been made to quantify 
CSCs on the basis of their demonstrated or 
presumed self-renewal activity in vitro. For 
leukaemias, the systems used to select for the 
most primitive cells have typically applied 
conditions that were developed for their nor-
mal counterparts. These involve co-culturing 
the cells on a stromal cell feeder layer28 (or on 
feeder cells engineered to produce stimula-
tory growth factors58,59), and the use of an end 
point that measures continued progenitor 
output (for example, the LTC-IC assay). For 
solid tumours, the most popular end point 
has been sphere formation in non-adherent 
culture containers14–18. However, such assays 
also have obvious caveats. One caveat is that 
factors important for the in vivo growth and 
self-renewal of some or all CSCs may not be 
provided by the in vitro conditions used. As a 
result, the cells being tested may show no or 
selected growth, and/or may be anomalously 
and rapidly induced to differentiate (enter a 
nondividing end state) without prior expan-
sion. Additionally, it is unlikely that either 
of these in vitro systems fully replicates the 
three-dimensional structure and environ-
ment of an in vivo tumour. Furthermore, the 
growth of malignant cells in vitro is usually 
limited to several weeks or months, during 
which time many cells typically differentiate 
or die, or transform into a clinically irrelevant 
population. Therefore, results obtained from 
such in vitro assays may be less useful for 
deriving clinically meaningful predictions.
Many human tumour cell lines, or pri-
mary tumour cells adapted for efficient 
maintenance in culture, have also been 
used as model sources of CSCs assayed by 
phenotype or growth assays in vitro or in 
transplanted mice. However, the extent to 
which the behaviour of such cells reflects the 
original genotype or tumour of origin is dif-
ficult to ascertain. Accordingly, considerable 
caution needs to be exercised in the types of 
questions in vitro passaged cells are used to 
address. Conversely, meta-analyses of can-
cer cell line responses to known anticancer 
drugs illustrate how these can be used to 
derive potential associations between some 
drug responses and the tissue of origin and 
genotype of the tumour cell line60.
In experimental settings, details that 
define the methods and end points used 
are clearly important. In particular, seem-
ingly innocuous parts of protocols, such 
as the duration and method of tissue dis-
sociation, may influence the subsets (sub-
clones) of CSCs that are detected. Similarly, 
when malignant cell lines are studied, the 
line should be specifically identified (for 
example, HCT116-propagating cells), and 
not assigned a more generic term (such as 
colon CSCs).
Experimental mouse models have also 
been invaluable contributors to progress 
in understanding the nature of CSCs. In 
this case, the role of specific genes in the 
spontaneous generation of tumours can 
be examined using transgenic technology, 
as well as transplantation assays that can 
use syngeneic recipients of any age. More 
recently, lineage tracing has been exploited 
to add further strong evidence of CSCs in 
glioblastomas, intestinal adenomas and 
epidermal tumours developing de novo in 
mice and, in the case of the glioblastoma, 
their anticipated drug resistance was also 
demonstrated61–63. These findings highlight 
how mouse models of tumorigenesis may 
facilitate the future development of methods 
for interrogating CSCs in patient samples for 
clinical purposes.
CSC niche: definition and open questions 
The concept of stem cell niches arises from 
observations that stem cells have discrete 
locations in tissues in vivo. Most CSCs are 
derived from cells in normal tissues in which 
local cues have an important regulatory 
role and have not yet acquired completely 
autonomous growth ability. In addition, 
recent evidence indicates that CSCs respond 
to antitumour agents differently in vitro 
and in vivo, reinforcing the concept that the 
niche in which a CSC is located may be an 
important determinant of how it responds 
to a given treatment. Several different cell 
types have been implicated in forming such 
niche environments, including fibroblasts, 
endosteal cells in the bone marrow, 
perivascular and vascular cells, and tissue 
Table 2 | Limitations of xenotransplant assays of human cancer stem cells 
Limitations Possible solutions
Short lifetime of mice Second-generation recipients or other animals
Altered homing of CSCs Orthotopic injection, humanized vasculature, 
humanized organs, humanized mice and 
growth-supporting synthetic scaffolds embedded in 
local tissue sites
Lack of cytokines that can stimulate 
growth of CSCs 
Injection of cytokines, cytokine-transgenic mice, 
humanized organs and humanized mice
Lack of tumour-specific 
microenvironment
Local injection of human microenvironmental cells, 
humanized mice and supportive scaffolds
Lack of intact immune cells; lack of 
natural immunosurveillance
Prior transplantation of CD34+ haematopoietic cells, 
humanized lymphoid organs, humanized mice and 
co-transplanation of immune cells (for example, NK cells)
CSC, cancer stem cell; NK, natural killer.
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macrophages3,11. However, little is known 
about the particular contributions of any 
of these cells, or how their effects on CSCs 
might be mediated at a molecular level. 
Whether, and to what extent, CSCs may 
contribute to important features of their 
microenvironment through autocrine or 
paracrine mechanisms, or even by creating 
clonal niche components, is also unclear.
Molecules anticipated to be involved 
in CSC–niche interactions include certain 
adhesion receptors, cytokine receptors, 
membrane-bound and soluble cytokine 
ligands, and various chemotactic factors. A 
noteworthy example is CXCR4, a receptor 
of stromal cell-derived factor 1 (SDF1; also 
known as CXCL12). CXCR4 is expressed 
on many cancer cells, and SDF1 is a niche-
derived chemoattractant for CXCR4+ cells, 
thereby enhancing their entry into the 
bone marrow64. These observations have 
led to the development of clinically effec-
tive drugs that inhibit CXCR4–SDF1 inter-
actions65,66 and that may be used to mobilize 
CSCs and possibly to sensitize them to 
therapy67. Conversely, CSCs often exhibit 
an acquired defect in their interaction with 
their specific microenvironments, leading 
to an abnormal or accelerated dissemina-
tion and metastasis formation64. CSC–niche 
interactions may also contribute to the 
acquisition of more aggressive properties 
by cells in solid tumours through the pro-
motion of a response referred to as an  
epithelial-to-mesenchymal transition (EMT).
Identifying therapeutic targets in CSCs
Principal modes of action of currently used 
anticancer agents on CSCs and the result-
ing (theoretical) outcomes are illustrated in 
FIG. 3 and Supplementary information S1 
(figure). Mechanisms that contribute to the 
responses exhibited by CSCs to known drugs 
are detailed in Supplementary information 
S2 (table). However, many cancers are not 
effectively eliminated by these strategies. 
Thus, a major goal in CSC research is to 
devise new strategies that will kill CSCs. 
To date, most efforts have focused either 
on searches for targets expressed in CSCs, 
but not in normal stem cells (CD34+ cells 
in human leukaemias or CD133+ or CD44+ 
cells isolated from solid tumours), or on 
screens for selective drugs or RNA interfer-
ence (RNAi) molecules that selectively kill 
CSCs over normal stem cells. Candidate 
therapeutic targets identified include various 
receptors and their oncogenic derivatives, 
adhesion molecules, antibody-accessible 
surface components, signalling intermedi-
ates, survival pathway elements, chromatin 
modifiers and metabolic targets68–90. Gene 
expression profiling, next-generation 
sequencing and increasingly sophisticated 
screening methods are anticipated to extend 
these lists in the near future.
However, most of these studies are at a 
necessarily early stage given all of the caveats 
in current CSC research. These include 
the unreliability of phenotype end points 
as rapid indicators of CSC responses, the 
low purity of CSC-enriched populations 
currently obtainable directly from patients 
(typically less than a few percent) and the 
unreliability of expression biomarkers to 
predict functional consequences. A good 
example of this unreliability is provided 
by the inability of CML stem cells to be 
efficiently killed by drugs that target the 
BCR-ABL kinase, even though CML stem 
cells express BCR-ABL91,92. Finally, even if 
some CSCs are responsive, the target may 
not be expressed or may already be mutated 
in other CSCs that might not even be present 
at a detectable level91. This would allow the 
malignant cell population to escape a partic-
ular targeted therapy and produce a relapse 
(FIG. 3; Supplementary information S1  
(figure)). Interactions between CSCs and 
their local microenvironment (niche) 
may also contribute to a lack of treatment 
response in vivo even when sensitivity is 
demonstrated in vitro. This has prompted 
interest in developing CSC-mobilizing strat-
egies, to render them potentially more  
susceptible even to conventional treatments67.
Evaluation of CSC eradication  
Although long-term disease-free survival 
after drug discontinuation might be 
considered to be a stringent (operational) 
indicator of clinical cure, solid criteria for 
complete disease eradication, and thus 
definitive cure, in cancer patients are difficult 
to define. In addition, the clinical need 
for complete disease eradication and the 
definition of cure have different meanings for 
individual patients. For example, aggressive 
approaches to eliminate all malignant cells 
may be counterindicated for patients with 
an otherwise (tumour-independent) limited 
life expectancy. Similarly, for patients who 
have diseases such as hairy cell leukaemia, 
the residual malignancy, including its stem 
cells, can remain indolent (pre-malignant) 
for years after the levels of tumour cells are 
initially reduced and, if they later increase, 
the cells are typically responsive to the same 
therapy as the original cells.
The use of xenotransplanted cells 
(for example, in NSG mice) is currently 
accepted as the best model for evaluating 
new drug candidates. However, the opti-
mal experimental design is not clear. The 
simplest first approach is to expose the test 
cells to the drug of interest ex vivo and to 
subsequently assay its effect by comparing 
the rate (or frequency) of tumour growth 
in NSG mice that are transplanted with 
control versus treated cells. However, the 
outcome may not reflect the response that 
would be seen following an in vivo treat-
ment after the tumour cells have been 
transplanted either before or after a regen-
erated malignant population has become 
detectable, depending on the magnitude of 
effect sought or expected. Complete and 
permanent disappearance of the malignant 
population after drug discontinuation 
would be a desirable outcome, but this is 
difficult to require as an experimental end 
point because of the cost and lack of knowl-
edge as to whether a more rapid indicator 
might be sufficient.
Importantly, owing to the relatively 
short lifespan of mice, even apparent cures 
in this model may not be sufficient to be 
clinically relevant. Secondary or tertiary 
transplants can be used to test for surviving 
CSCs, but again the predictive relevance of 
the results is unknown. Furthermore, most 
xenotransplantation methods have restricted 
quantitative power, being generally limited 
to the detection of less than 100-fold reduc-
tions in CSC numbers, but lasting benefits 
in patients may require much larger reduc-
tions. Thus, even the most dramatic effects 
obtained in any transplant cancer model 
need to be interpreted with caution. This 
issue will probably become increasingly 
important in the face of emerging data on 
the vast genomic and epigenomic hetero-
geneity of many tumours6–8 indicative of 
subclones that would be well below the cur-
rent limit of CSC detection. Conversely, in 
some instances, what may seem to be small 
(less than tenfold) reductions in tumour 
growth or CSC numbers in a transplant 
model, may prove of significant value clini-
cally. Together, these issues highlight the 
emerging importance of correlative stud-
ies that might guide the development of 
predictive end points for particular tumour 
responses to specific agents.
In cancer patients, the possibility of 
detecting minimal residual disease (MRD) 
by sensitive molecular markers (for exam-
ple, quantitative PCR) or other measures93 
is an important aspect of disease manage-
ment. However, depending on the type of 
neoplasm, persistent MRD may not neces-
sarily argue against long-term disease-free 
survival. In AML, it has been reported that 
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certain features of CSC-enriched popula-
tions correlate with clinical responses to 
conventional treatments94–97. Conversely, 
in chronic phase CML, the persistence of a 
detectable (that is, substantial) population of 
primitive (presumably pre-malignant) CML 
stem cells is not predictive of relapse98.
Routine assays for MRD used clinically 
may, however, be unable to distinguish 
a new (often indolent or pre-malignant) 
subclone from the original dominant one. 
Interestingly, non-malignant clones bear-
ing the genetic hallmarks of malignant 
clones have been reported to be commonly 
present at detectable levels in normal 
individuals99–102. Whole-genome sequenc-
ing now offers an approach to discrimi-
nate different subclones and their clonal 
relationships and mode of evolution with 
unprecedented power, particularly if this 
methodology can be made usefully 
applicable to blood or other body fluids103. 
Thus, as sequencing costs decrease, it 
seems likely that such approaches will aid 
the use of MRD assessments to predict the  
likelihood of relapse.
Summary
The CSC hypothesis provides a model that 
accommodates the multiple causes of hetero-
geneity that characterize human malignan-
cies as they evolve. Such heterogeneity exists 
not only between the same types of cancer 
arising in different individuals, but also 
within the malignant cell population that 
forms in an individual patient. This is due 
to the fact that the formation of a cancer 
involves the genesis and continuous diversi-
fication of subclones that become abnor-
mally and non-homogeneously distributed, 
as they acquire an increasingly unstable 
control of many properties, including their 
ability to continue to proliferate. At an early 
stage in this process, a hierarchy that recapit-
ulates features of the differentiation process 
of the tissue of origin is often still apparent. 
The associated experimental observation 
that only a small, phenotypically distinguish-
able subset of the malignant cells is capable 
of generating a malignant population when 
transplanted into immunodeficient mice is 
the experimental basis of inferring the exist-
ence of a CSC population. The CSC concept 
is of key importance clinically because it 
predicts that cures require strategies that will 
eliminate CSC populations, as these cells sit 
at the top of any residual hierarchies within 
the malignant population. However, addi-
tional elimination of pre-malignant, as well 
as malignant, stem cells, is likely to be neces-
sary in many patients to achieve a sustained 
disease-free outcome or even definitive cure.
Although experiments with many pri-
mary tumours suggest that they fit a CSC 
model, increasing complexity and diversity 
in the composition, location and behaviour 
of members of individual malignant popula-
tions has led to confusion and controversy 
about the utility and validity of the CSC 
Figure 3 | Effects of therapies. When most cancer stem cells (CSCs) sur-
vive therapy, an early relapse follows (part a). However, even after having 
successfully eradicated a dominant subclone (or even many other relevant 
subclones), the disease may relapse from a pre-malignant neoplastic stem 
cell (NSC)  (part b). In this case late relapses may occur, with variable and 
unpredictable latency periods, depending on the time required for the 
accumulation of further hits in these subclone-specific (stem) cells to enable 
them to become fully malignant; that is, to transform into CSCs. Accordingly, 
relapses may occur months to decades later, and the relapsing cancer may 
display very different features and response to treatment. 
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concept. Many of these issues can be attrib-
uted to the multistep origin, and the now 
well-documented heterogeneity of CSCs that 
reflects the multitude of driver and passen-
ger epigenetic and genetic perturbations that 
these cells accumulate during their evolu-
tion. As a result, phenotypic plasticity super-
imposed on a multiplicity of pre-malignant 
and malignant subclones are features now 
recognized as common in neoplastic popula-
tions by the time they become symptomatic. 
In some advanced neoplasms, these changes 
may result in the majority of the cells hav-
ing overt or unstable CSC properties. At 
the opposite extreme are early stage cancer 
lesions, where the pre-malignant neoplas-
tic stem cells may not already possess, and 
may not necessarily ever acquire, full CSC 
activity.
None of these observations negates the 
central value of the CSC concept. Rather, 
they highlight its importance as an element 
that is likely to be crucial in understanding 
the complex and patient-specific evolution-
ary process by which human malignan-
cies develop their genetic and epigenetic 
diversity. Accordingly, the CSC concept is 
likely to have increasing importance as new 
tools for diagnosing cancers at earlier stages 
become available. In this respect, increased 
precision in the details of the methods used 
and described in identifying CSCs will be 
central to progress in improving patient 
management.
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